A Trial of Neuroprotection With ACTH in Acute Optic Neuritis (ACTHAR)
A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis
Sponsor: Mallinckrodt
Terminated
Sponsor requested
Other terminated trials from Mallinckrodt
Other Multiple Sclerosis trials with similar outcome
Listed as NCT01838174, this PHASE4 trial focuses on Multiple Sclerosis and remains terminated or withdrawn. Sponsored by Mallinckrodt, it has been updated 12 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
May 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Mar 2022 — May 2023 [monthly]
Terminated PHASE4
Status: Active Not Recruiting → Terminated
-
Nov 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE4
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Nov 2019 — Dec 2020 [monthly]
Recruiting PHASE4
-
Nov 2018 — Nov 2019 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Unknown Status PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE4
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mallinckrodt
- University of Colorado, Denver
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .